-- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle --
-- No treatment-related adverse events (TRAEs) or dose-limiting toxicities (DLTs) observed to date, including no rash or gastrointestinal (GI) AEs --
-- Systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities --
-- Half-life of approximately 70 hours supports once-daily or less frequent oral dosing --
-- Distinctive MEK inhibitor profile for the treatment of both NF1-related plexiform and cutaneous neurofibromas, cancer, and other opportunities --
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.